Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Jan 25, 2019

(R) Cantargia: first patient treated with antibody CAN04 in the phase IIa part of CANFOUR trial

Dec 10, 2018

(R) Cantargia presents new positive preclinical data on antibody CAN04 at major antibody conference

Dec 7, 2018

(R) Cantargia: Phase I safety evaluation part of CANFOUR trial of antibody CAN04 completed and phase IIa part being initiated

Nov 15, 2018

(R) Cantargia publishes interim report for third quarter of 2018

Oct 30, 2018

(R) Cantargia AB: Nomination Committee appointed ahead of 2019 Annual General Meeting

Oct 20, 2018

(R) Cantargia presented positive phase I clinical data with lead candidate CAN04 at ESMO

Oct 9, 2018

(R) Cantargia presents clinical data from its ongoing CANFOUR trial at ESMO

Oct 1, 2018

(R) Cantargia obtains patent in USA for the antibody CAN03

Sep 19, 2018

(R) Cantargia publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market

Sep 19, 2018

(R) Cantargia obtains patent approval for the antibody CAN04 (nidanilimab) in Japan

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye